/
BLFS
$28.30-$0.37 (-1.29%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.4B
49M shares
52-week range
$17.86 – $30.00
86% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.98%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-16.21
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.7M | $27.4M | $48.1M | $119.2M | $76.2M | $75.9M | $82.3M | $96.2M |
| Cost of revenue | $6.2M | $8.9M | $20.6M | $90.3M | $29.3M | $96.5M | $28.6M | $34.1M |
| Gross profit | $13.5M | $18.5M | $27.4M | $28.8M | $46.9M | $46.8M | $53.7M | $62.1M |
| Gross margin | 68.5% | 67.6% | 57.1% | 24.2% | 61.5% | 61.6% | 65.3% | 64.6% |
| R&D | $1.3M | $4.1M | $6.7M | $11.8M | $14.8M | $18.8M | $7.9M | $7.6M |
| Operating income | $3.7M | −$781.0K | −$3.3M | −$35.2M | −$5.9M | −$23.4M | −$7.1M | −$1.1M |
| EBITDA | −$24.7M | −$884.0K | $1.5M | −$16.7M | −$124.2M | −$45.2M | $1.5M | $3.6M |
| Net income | $3.3M | −$1.7M | $2.7M | −$8.9M | −$139.8M | −$66.4M | −$20.2M | −$12.1M |
| Net margin | 16.5% | -6.1% | 5.5% | -7.5% | -183.4% | -87.6% | -24.5% | -12.6% |
| EPS (diluted) | -1.56 | -0.09 | -0.06 | -0.23 | -3.29 | -1.52 | -0.44 | -0.25 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $114M | $0.14 | $0.04–$0.24 | 3 |
| 2027 | $134M | $0.32 | $0.25–$0.39 | 3 |
| 2028 | $165M | $0.85 | $0.83–$0.86 | 1 |
| 2029 | $200M | $1.29 | $1.26–$1.31 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
www.biolifesolutions.com- Employees
- 155
- IPO / List date
- Nov 22, 1989
- HQ
- BOTHELL, WA
Held by traders on TradeandTell
No one on the platform currently holds BLFS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 207,128 | $4.0M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2014-01-29 | 1-for-14reverse |
Recent trades on TradeandTell
No one on the platform has traded BLFS yet.
